Cipla reported muted growth in revenue YoY, largely due to India, SAGA, and API revenue growth being weak. India growth was lower YoY due to the high base effect with higher COVID 19 product sales in Q1FY22. The company has launched 16 new products in the anti- ophthalmology therapy segments in India.